| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Offer E Edelstei. Attitudes and beliefs of medicine and social work students about medical cannabis use for epilepsy. Epilepsy & behavior : E&B. vol 127. 2022-01-09. PMID:34999501. |
prior recreational cannabis use [or=1.541] and having friends who recreationally use the substance [or=1.891] were associated with the belief that mc is an effective therapy for epilepsy. |
2022-01-09 |
2023-08-13 |
human |
| Anastasia Suraev, Melissa J Benson, Lewis Martin, Nicholas Lintzeris, Iain S McGrego. Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: A sub-analysis of the 'PELICAN' study. Epilepsy & behavior : E&B. vol 127. 2021-12-26. PMID:34954507. |
determination of contaminants in artisanal cannabis products used for childhood epilepsy in the australian community: a sub-analysis of the 'pelican' study. |
2021-12-26 |
2023-08-13 |
Not clear |
| Anastasia Suraev, Melissa J Benson, Lewis Martin, Nicholas Lintzeris, Iain S McGrego. Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: A sub-analysis of the 'PELICAN' study. Epilepsy & behavior : E&B. vol 127. 2021-12-26. PMID:34954507. |
in the present analysis, 78 samples of cannabis products collected (as part of a previous study) from families of children with epilepsy (average age 8.8 ± 4.6 years) were analyzed for heavy metals (arsenic, cadmium, lead, and mercury), residual solvents (panel of 19 solvents) and pesticides (panel of 57 pesticides). |
2021-12-26 |
2023-08-13 |
Not clear |
| Maryam Nabavi Nouri, Maria Zak, Puneet Jain, Robyn Whitne. Epilepsy Management in Tuberous Sclerosis Complex: Existing and Evolving Therapies and Future Considerations. Pediatric neurology. vol 126. 2021-12-08. PMID:34740132. |
several new therapies such as preemptive vigabatrin therapy in infants, cannabidiol, and mtor inhibitors have emerged in recent years for the treatment of epilepsy in tsc. |
2021-12-08 |
2023-08-13 |
Not clear |
| Brittney H Davis, T Mark Beasley, Michelle Amaral, Jerzy P Szaflarski, Tyler Gaston, Leslie Perry Grayson, David G Standaert, E Martina Bebin, Nita A Limd. Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy. Clinical pharmacology and therapeutics. vol 110. issue 5. 2021-11-30. PMID:34464454. |
pharmacogenetic predictors of cannabidiol response and tolerability in treatment-resistant epilepsy. |
2021-11-30 |
2023-08-13 |
Not clear |
| Brittney H Davis, T Mark Beasley, Michelle Amaral, Jerzy P Szaflarski, Tyler Gaston, Leslie Perry Grayson, David G Standaert, E Martina Bebin, Nita A Limd. Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy. Clinical pharmacology and therapeutics. vol 110. issue 5. 2021-11-30. PMID:34464454. |
in patients with treatment-resistant epilepsy (tre), cannabidiol (cbd) produces variable improvement in seizure control. |
2021-11-30 |
2023-08-13 |
Not clear |
| Lyndsey L Anderson, Marika Heblinski, Nathan L Absalom, Nicole A Hawkins, Michael T Bowen, Melissa J Benson, Fan Zhang, Dilara Bahceci, Peter T Doohan, Mary Chebib, Iain S McGregor, Jennifer A Kearney, Jonathon C Arnol. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British journal of pharmacology. vol 178. issue 24. 2021-11-29. PMID:34384142. |
cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. |
2021-11-29 |
2023-08-13 |
mouse |
| Lyndsey L Anderson, Marika Heblinski, Nathan L Absalom, Nicole A Hawkins, Michael T Bowen, Melissa J Benson, Fan Zhang, Dilara Bahceci, Peter T Doohan, Mary Chebib, Iain S McGregor, Jennifer A Kearney, Jonathon C Arnol. Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British journal of pharmacology. vol 178. issue 24. 2021-11-29. PMID:34384142. |
cannabis has been used to treat epilepsy for millennia, with such use validated by regulatory approval of cannabidiol (cbd) for dravet syndrome. |
2021-11-29 |
2023-08-13 |
mouse |
| J T Houston, R Nenert, J B Allendorfer, E M Bebin, T E Gaston, A M Goodman, J P Szaflarsk. White matter integrity after cannabidiol administration for treatment resistant epilepsy. Epilepsy research. vol 172. 2021-11-25. PMID:33725662. |
white matter integrity after cannabidiol administration for treatment resistant epilepsy. |
2021-11-25 |
2023-08-13 |
human |
| J T Houston, R Nenert, J B Allendorfer, E M Bebin, T E Gaston, A M Goodman, J P Szaflarsk. White matter integrity after cannabidiol administration for treatment resistant epilepsy. Epilepsy research. vol 172. 2021-11-25. PMID:33725662. |
in the current study, we analyzed the effects of pharmaceutical grade cannabidiol oral solution (cbd; epidiolex® in the u.s.; epidyolex® in the eu; 100 mg/ml oral solution) on white matter integrity using diffusion mri in patients with treatment resistant epilepsy (tre). |
2021-11-25 |
2023-08-13 |
human |
| Antuan Divisic, Irene Avagnina, Valentina De Tommasi, Anna Santini, Laura Brogelli, Luca Giacomelli, Franca Benin. The use of medical cannabis in pediatric palliative care: a case series. Italian journal of pediatrics. vol 47. issue 1. 2021-11-25. PMID:34802466. |
medical cannabis may be a useful tool for managing treatment-resistant epilepsy and chronic pain, which affect many patients in pediatric palliative care (ppc); however, little evidence is available in this setting. |
2021-11-25 |
2023-08-13 |
Not clear |
| Carlos A Pérez Montilla, Paula S Schaiquevich, Paulo Cáceres Guido, Roberto H Caraballo, Gabriela Reyes Valenzuela, Cintia V Cruz, Facundo García Bournisse. An Ultrafast Ultrahigh-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for Cannabidiol Monitoring in Pediatric Refractory Epilepsy. Therapeutic drug monitoring. vol 43. issue 5. 2021-11-17. PMID:33346629. |
an ultrafast ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry method for cannabidiol monitoring in pediatric refractory epilepsy. |
2021-11-17 |
2023-08-13 |
Not clear |
| Carlos A Pérez Montilla, Paula S Schaiquevich, Paulo Cáceres Guido, Roberto H Caraballo, Gabriela Reyes Valenzuela, Cintia V Cruz, Facundo García Bournisse. An Ultrafast Ultrahigh-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for Cannabidiol Monitoring in Pediatric Refractory Epilepsy. Therapeutic drug monitoring. vol 43. issue 5. 2021-11-17. PMID:33346629. |
cannabidiol (cbd) is a nonpsychoactive natural product that has been increasingly used as a promising new drug for the management of neurological conditions such as refractory epilepsy. |
2021-11-17 |
2023-08-13 |
Not clear |
| Aviv Amirav, Benny Neumark, Ksenia J Margolin Eren, Alexander B Fialkov, Noam Ta. Cannabis and its cannabinoids analysis by gas chromatography-mass spectrometry with Cold EI. Journal of mass spectrometry : JMS. vol 56. issue 6. 2021-11-15. PMID:33955098. |
finally, cannabis drugs such as ep-1 used in israel for treatment of epilepsy and for children with autism spectrum disorder (asd) were analyzed for their full cannabinoids content for learning on the entourage effect and for drug activity optimization. |
2021-11-15 |
2023-08-13 |
Not clear |
| Christopher L Anderson, Victoria Evans, Laura Gorham, Zhao Liu, Cynthia R Johnson, Paul R Carne. Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsy & behavior : E&B. vol 124. 2021-11-15. PMID:34560358. |
to evaluate the effects of oral pharmacological cannabidiol (cbd) on seizures, side effects, quality of life, behavior, mood, and sleep in children with drug-resistant epilepsy (dre) during a phase ii, prospective, open-label clinical study. |
2021-11-15 |
2023-08-13 |
Not clear |
| Tyler E Gaston, Roy C Martin, Jerzy P Szaflarsk. Cannabidiol (CBD) and cognition in epilepsy. Epilepsy & behavior : E&B. vol 124. 2021-11-15. PMID:34563808. |
cannabidiol (cbd) and cognition in epilepsy. |
2021-11-15 |
2023-08-13 |
human |
| Tyler E Gaston, Roy C Martin, Jerzy P Szaflarsk. Cannabidiol (CBD) and cognition in epilepsy. Epilepsy & behavior : E&B. vol 124. 2021-11-15. PMID:34563808. |
anecdotal reports of the benefits of cannabis and its components in the treatment of epilepsy have been reported for millennia. |
2021-11-15 |
2023-08-13 |
human |
| Tyler E Gaston, Roy C Martin, Jerzy P Szaflarsk. Cannabidiol (CBD) and cognition in epilepsy. Epilepsy & behavior : E&B. vol 124. 2021-11-15. PMID:34563808. |
however, only recently randomized controlled trial data in support of cannabidiol (cbd) became available resulting in its fda approval for the treatment of seizures and epilepsy. |
2021-11-15 |
2023-08-13 |
human |
| Zachary H McCann, Magdalena Szaflarski, Jerzy P Szaflarsk. A feasibility study to assess social stress and social support in patients enrolled in a cannabidiol (CBD) compassionate access program. Epilepsy & behavior : E&B. vol 124. 2021-11-15. PMID:34600280. |
cannabidiol (cbd) trials offer an opportunity to examine social factors that shape outcomes of patients with treatment-resistant epilepsy. |
2021-11-15 |
2023-08-13 |
Not clear |
| Kerstin A Klotz, Daniel Grob, Jan Schönberger, Lea Nakamura, Birgitta Metternich, Andreas Schulze-Bonhage, Julia Jacob. Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study. CNS drugs. vol 35. issue 11. 2021-11-09. PMID:34687005. |
effect of cannabidiol on interictal epileptiform activity and sleep architecture in children with intractable epilepsy: a prospective open-label study. |
2021-11-09 |
2023-08-13 |
Not clear |